scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX® Indication to Include the Treatment of Edema in Patients with Chronic Kidney Disease

Stock Information for scPharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About scPharmaceuticals Inc.

MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BRY, SCPH, WKHS on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ZIMV, ARIS, SCPH on Behalf of Shareholders
SCPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of scPharmaceuticals Inc. - SCPH
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SHCO, VRNT, SCPH on Behalf of Shareholders
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger - GTLS, SCPH, VTLE, and VRNT
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NWE, BKH, MURA, SCPH on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates IMXI, HBI, VTLE, SCPH on Behalf of Shareholders

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.